One in three suffer from a brain disease or cancer and currently, there are no “cures”, as drugs do not reach the brain at viable doses. New drugs for brain diseases have the lowest success rate compared to other therapeutic areas and current animal models are unreliable to inform translation. Our patented platform technology, GFiberS, allows peptide therapies administered via nose-to-brain delivery to target specific receptors in the brain producing a therapeutic effect. GFiberS are manufactured under continuous and industrial amenable processes and our team is pioneering proprietary human nose-to-brain-on-chip models for speeding up the translation of brain therapies.